title: Alzheimer disease: CSF biomarkers could be used in Aβ immunotherapy trials for AD.
authors.forename: Iley
authors.initials: I
authors.lastname: Ozerlat
mesh_terms: D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015337:Multicenter Studies as Topic; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D016229:Amyloid beta-Peptides; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D016875:tau Proteins; C545458:bapineuzumab